These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1189 related articles for article (PubMed ID: 27936049)

  • 21. Clinical and pathological characteristics of incidental and nonincidental papillary thyroid microcarcinoma in 339 patients.
    Vasileiadis I; Karatzas T; Vasileiadis D; Kapetanakis S; Charitoudis G; Karakostas E; Kouraklis G
    Head Neck; 2014 Apr; 36(4):564-70. PubMed ID: 23780707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Surgery; 2015 Dec; 158(6):1500-11. PubMed ID: 26120069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
    Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF analysis before surgery for papillary thyroid carcinoma: correlation with clinicopathological features and prognosis in a single-institution prospective experience.
    Galuppini F; Pennelli G; Vianello F; Censi S; Zambonin L; Watutantrige-Fernando S; Manso J; Nacamulli D; Lora O; Pelizzo MR; Rugge M; Barollo S; Mian C
    Clin Chem Lab Med; 2016 Sep; 54(9):1531-9. PubMed ID: 26863344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors.
    Choi SY; Park H; Kang MK; Lee DK; Lee KD; Lee HS; Kim SW; Lee EN; Hong JC
    World J Surg Oncol; 2013 Nov; 11():291. PubMed ID: 24228637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tall cell variant of papillary thyroid microcarcinoma: clinicopathologic features with BRAF(V600E) mutational analysis.
    Bernstein J; Virk RK; Hui P; Prasad A; Westra WH; Tallini G; Adeniran AJ; Udelsman R; Sasaki CT; Roman SA; Sosa JA; Prasad ML
    Thyroid; 2013 Dec; 23(12):1525-31. PubMed ID: 23682579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
    Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of coexistent Hashimoto's thyroiditis on lymph node metastasis and prognosis in papillary thyroid microcarcinoma.
    Qu N; Zhang L; Lin DZ; Ji QH; Zhu YX; Wang Y
    Tumour Biol; 2016 Jun; 37(6):7685-92. PubMed ID: 26692097
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of risk factors of central lymph node metastasis and evaluation of the effect of prophylactic central neck dissection on migration of staging and risk stratification in patients with clinically node-negative papillary thyroid microcarcinoma.
    Yuan J; Li J; Chen X; Lin X; Du J; Zhao G; Chen Z; Wu Z
    Bull Cancer; 2017 Jun; 104(6):516-523. PubMed ID: 28476312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
    Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
    Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of central lymph node metastasis in patientswith thyroid papillary microcarcinoma.
    Akın Ş; Yazgan Aksoy D; Akın S; Kılıç M; Yetişir F; Bayraktar M
    Turk J Med Sci; 2017 Dec; 47(6):1723-1727. PubMed ID: 29306230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathological, immunohistochemical factors and recurrence associated with extrathyroidal extension in papillary thyroid microcarcinoma.
    Kim WY; Kim HY; Son GS; Bae JW; Lee JB
    J Cancer Res Ther; 2014; 10(1):50-5. PubMed ID: 24762486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Association between BRAF V600E mutation and central lymph node metastasis in patients with papillary thyroid carcinoma].
    Shi C; Qin H; Ding C; Sun Y; Lyu Y; Shi T
    Zhonghua Zhong Liu Za Zhi; 2015 Feb; 37(2):123-7. PubMed ID: 25975689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.
    Choi YW; Kim YH; Lee J; Soh EY; Park TJ; Kim JH
    Hum Pathol; 2015 Oct; 46(10):1557-65. PubMed ID: 26297257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Papillary thyroid carcinoma and microcarcinoma: is there a need to distinguish the two?
    Arora N; Turbendian HK; Kato MA; Moo TA; Zarnegar R; Fahey TJ
    Thyroid; 2009 May; 19(5):473-7. PubMed ID: 19348582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic implication of histological features associated with EHD2 expression in papillary thyroid carcinoma.
    Kim Y; Kim MH; Jeon S; Kim J; Kim C; Bae JS; Jung CK
    PLoS One; 2017; 12(3):e0174737. PubMed ID: 28358874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of molecular markers and tumor histological type in central lymph node metastasis of papillary thyroid carcinoma.
    Paulson L; Shindo M; Schuff K; Corless C
    Arch Otolaryngol Head Neck Surg; 2012 Jan; 138(1):44-9. PubMed ID: 22249628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
    Elisei R; Ugolini C; Viola D; Lupi C; Biagini A; Giannini R; Romei C; Miccoli P; Pinchera A; Basolo F
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3943-9. PubMed ID: 18682506
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis.
    Kim SK; Song KH; Lim SD; Lim YC; Yoo YB; Kim JS; Hwang TS
    Thyroid; 2009 Feb; 19(2):137-41. PubMed ID: 19014278
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The BRAFT1799A mutation is not associated with occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma.
    Wan HF; Zhang B; Yan DG; Xu ZG
    Asian Pac J Cancer Prev; 2015; 16(7):2947-51. PubMed ID: 25854387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 60.